Pharmacologic Treatment of Pulmonary Embolism

Keyphrases

• Pulmonary Embolism 100%
• Pharmacological Therapy 100%
• Anticoagulants 100%
• Patient Characteristics 50%
• Clinical Presentation 50%
• Clinical Setting 50%
• Initial Treatment 50%
• Comorbidity 50%
• Low Risk 50%
• Clinical High Risk 50%
• Life-limiting Conditions 50%
• Treatment Choice 50%
• Extended Duration 50%
• Acute Phase 50%
• Anticoagulation 50%
• Treatment Phase 50%
• Patient-centered 50%
• Patient Selection 50%
• Direct Oral Anticoagulants 50%
• Heparin 50%
• Bleeding Risk 50%
• Catheter 50%
• Low Molecular Weight Heparin 50%
• Anticoagulant Therapy 50%
• Pharmacological Properties 50%
• Vitamin K Antagonists 50%
• Pulmonary Artery 50%
• Risk Stratification 50%
• Low-risk Patients 50%
• Acute Pulmonary Embolism 50%
• Recurrence Prevention 50%
• Thrombolytic Therapy 50%
• Stable Patients 50%
• Intermediate Risk 50%
• Cardiac Biomarkers 50%
• Right Ventricle Function 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Lung Embolism 100%
• Anticoagulant Agent 66%
• Recurrent Disease 66%
• Biological Marker 33%
• Bleeding 33%
• Heparin 33%
• Low Molecular Weight Heparin 33%
• Antivitamin K 33%
• Fibrinolytic Agent 33%
• Direct Oral Anticoagulant 33%
• Comorbidity 33%
• Preference 33%